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n-6 PUFAs and/or individual n-3 or n-6 PUFAs in at least one 
of the specific population groups: 10 in pregnant women, 
4 in lactating women, 3 in infants 6–12 months, 6 in children 
1–3 years, 11 in children 4–9 years, 8 in adolescents 10–18 
years and 11 in elderly >65 years. Mean linoleic acid intake 
was within the recommendation (4 energy percentage [E%]) 
in 52% of the countries, with inadequate intakes more likely 
in lactating women, adolescents and elderly. Mean α-linolenic 
acid intake was within the recommendation (0.5 E%) in 77% 
of the countries. In 26% of the countries, mean eicosapen-
taenoic acid and/or docosahexaenoic acid intake was as rec-
ommended. These results indicate that intake of n-3 and n-6 
PUFAs may be suboptimal in specific population groups in 
Europe.  © 2017 The Author(s)
Published by S. Karger AG, Basel 
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 Abstract 
 Background: Earlier reviews indicated that in many coun-
tries adults, children and adolescents consume on an aver-
age less polyunsaturated fatty acids (PUFAs) than recom-
mended by the Food and Agriculture Organisation/World 
Health Organisation.  Summary: The intake of total and indi-
vidual n-3 and n-6 PUFAs in European infants, children, ado-
lescents, elderly and pregnant/lactating women was evalu-
ated systematically.  Results: The evaluations were done 
against recommendations of the European Food Safety 
 Authority.  Key Messages: Fifty-three studies from 17 differ-
ent European countries reported an intake of total n-3 and 
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 N-3 and n-6 polyunsaturated fatty acids (PUFAs) – 
particularly the longer chain, more unsaturated members 
of these families, and also the plant-derived essential 
members – play a vital role in human health from concep-
tion onwards: through every stage of human develop-
ment, maturation and aging, including roles in cell mem-
brane composition, metabolism, signal transduction and 
amplification, and in gene expression  [1] . An adequate 
intake (AI) of PUFAs is of critical importance during ear-
ly life and plays an essential role in supporting growth and 
development. In addition, for the general population an 
AI of n-3 and n-6 PUFAs is recommended for the preven-
tion of cardiovascular diseases  [2] . However, specific 
population groups may have relatively higher require-
ments of these fatty acids and thus are more at risk of in-
adequate intake. These specific population groups in-
clude pregnant and lactating women because of increased 
PUFA requirements for growth, neurological and im-
mune function of their infants  [3, 4] . Similarly, infants, 
children and adolescents have relatively high nutrient re-
quirements compared to adults to support rapid growth 
and development, but complementary foods, school 
meals and dietary habits during childhood and adoles-
cence may not provide sufficient amounts of nutrients, 
notably PUFAs  [5–8] . Finally, elderly have altered nutri-
ent requirements because of changes in body composi-
tion and physical activity and the presence of disease, and 
altered nutrient intake because of low variety of food con-
sumed, reduced appetite, loss of sensory appreciation of 
food, dentition and swallowing problems, the presence of 
disease and social issues, and thus may be at risk of inad-
equate PUFA intake, besides other important micronu-
trients  [9] . 
 Recent reviews on dietary fat and fatty acid intake in 
different countries around the world  [10–14] are mainly 
based on data from national dietary surveys that do not 
include a representative subsample of these specific sub-
groups of the population. Moreover, in many of these di-
etary surveys, intake data of individual PUFAs are not 
reported. Therefore, the aim of this systematic review is 
to evaluate the available data on n-3 and n-6 PUFA intake 
in 7 specific population groups in Europe: (1) pregnant 
women, (2) lactating women, (3) infants (6–12 months), 
(4) young children (1–3 years), (5) older children (4–10 
years), (6) adolescents (10–18 years) and (7) elderly (>65 
years). First, an overview of the current available recom-
mendations for PUFA intake in European countries is 
given. Second, the available intake data are summarised 
and reported for each group, followed by a discussion of 
the gaps between reported intake and the European Food 
Safety Authority (EFSA) recommendations. Third, an 
overview of studies describing the main food sources of 
the various PUFAs in these population groups is present-
ed. 
 Methods 
 A more detailed description of the methods employed is given 
in online supplementary text 1 (for all online suppl. material, see 
www.karger.com/doi/10.1159/000456723).
 Evaluation of Current Recommendations for PUFA Intake in 
European Countries 
 For the evaluation of current recommendations for PUFA in-
take in European countries, we updated the systematic review on 
dietary reference intake, nutritional goals and dietary guidelines 
for fats and fatty acids by Aranceta and Pérez-Rodrigo  [15] that 
was published in 2012 with PUFA recommendations for specific 
population groups in Europe, using the search strategy by Arance-
ta and Pérez-Rodrigo  [15] , excluding trans fatty acids. The search 
was conducted using PubMed and Scopus from January 2011 (date 
of Aranceta search) to April 20, 2015. In addition, a manual search 
on individual European country recommendations was performed 
via Google with latest update done in October 2016. 
 Evaluation of Current Intake of Total and Specific N-3 
and N-6 PUFAs in the European Diet for Specific 
Population Groups 
 Criteria for Considering Studies in This Review 
 Type of study. Observational studies and national dietary sur-
veys were the primary focus of this review. Randomised control 
trials or other experimental studies were included only if they re-
ported baseline data and/or data for the control group. 
 Type of exposure. Studies were included if they reported data on 
intake of at least one of the following: α-linolenic acid (ALA), 
eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), doc-
osahexaenoic acid (DHA), total n-3 PUFAs, linoleic acid (LA), ar-
achidonic acid (ARA) or total n-6 PUFAs. We excluded studies 
reporting only the total PUFA intake without any distinction on 
individual classes as mentioned above. 
 Type of population. The following 7 subgroups of the popula-
tion were the focus of interest in this review: pregnant women, 
lactating women, infants (6–12 months), young children 
(1–3  years), older children (4–10 years), adolescents (10–18 
years), elderly (>65 years). The age ranges are defined in accor-
dance with the EFSA Comprehensive European Consumption 
Database  [16] . Studies in specific disease populations were ex-
cluded. Only studies conducted in European countries were in-
cluded. Inclusion and exclusion criteria can be found in the ab-
stract review form at  PROSPERO with registration number 
CRD42014014717.
 Period of time for exposure measurement. Studies conducted 
after January 1, 2000 were eligible for inclusion. Studies conducted 
before 2000, but reported in a publication published after 2000, 
were excluded. 
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 Search Methods for Identification of Studies 
 PubMed, Scopus and Cochrane Central Register of  Controlled 
Trials (CENTRAL) databases were searched for papers pub-
lished from January 2000 until November 2015, using text words 
with appropriate truncation and relevant indexing terms. The 
search was in the form (n-3 and n-6 PUFA terms) and (terms 
for intake) and (terms for the specific subgroup considered) and 
(limit to humans) and (limit to 2000 – current). The full search 
strategy for the Ovid MEDLINE database can be accessed via 
PROSPERO file CRD42014014717; the searches of other data-
bases were based on this strategy. Reference lists of all eligible 
papers and relevant systematic reviews were searched for addi-
tional studies. 
 Data Selection 
 The titles and abstracts of studies identified by the search were 
screened by a single reviewer, and clearly irrelevant studies were 
excluded. The full text reports of all potentially relevant studies 
were obtained and assessed independently for eligibility by 2 inde-
pendent reviewers. The systematic review software Covidence 
(www.covidence.org) was used to facilitate screening of literature. 
Any disagreement was resolved by discussion.
 Data Extraction 
 Standardised forms were used for data extraction and manage-
ment. For each included study, the following data were extracted 
and brought together into one large database: name of first author, 
year of publication, year(s) of data collection, participant charac-
teristics (age, sex,  n , the subgroup they belong to), method used for 
dietary assessment and intake data on total energy (MJ/day), total 
fat (g/day and energy percentage [E%]), total PUFAs (g/day and 
E%), total n-6 PUFAs (g/day and E%), LA (g/day and E%), ARA 
(mg/day), total n-3 PUFAs (g/day and E%), ALA (g/day and 
E%), EPA (mg/day), DPA (mg/day), and DHA (mg/day). When 
necessary, units of measurement were converted to a standard 
form (g/day, mg/day, or E%) expressed in mean and SD to facilitate 
comparison across studies. When only median and quartiles were 
given, the mean was calculated as the average of the median, 25th 
(P25) and 75th (P75) percentiles. The standard deviation was cal-
culated as P75-P25/1.35. Unpublished data for countries that par-
ticipated in the HELENA study in adolescents were included based 
on personal communication with the researchers involved, as the 
original publication only reported data of the overall international 
sample  [17] .
 Data Assessment 
 All fatty acid intake data were evaluated against the EFSA rec-
ommendations  [18] , which are the most recent recommendations 
that are set by a recognised Europe-wide health authority. Because 
of the absence of total n-3 and total n-6 PUFA intake recommen-
dations, ALA and LA recommendations were used to evaluate to-
tal n-3 or n-6 PUFA intake. ALA and LA are the biggest contribu-
tors to total n-3 and n-6 PUFA intake, respectively. Per country 
and population group, intake data were extracted to evaluate 
whether the intake of different PUFAs was in line with the EFSA 
recommendations. Where multiple datasets were available for one 
country and specific population group, the average of these datas-
ets was calculated (weighted for  n ). This average was used to define 
whether the intake data were in line or below the relevant EFSA 
recommendation. 
 Evaluation of Major Dietary Contributors to PUFA Intake 
 Another literature search was undertaken in PubMed to find 
data on dietary sources of PUFAs in the considered population 
subgroups and data on the PUFA composition of human milk. The 
search was conducted with terms describing fatty acids, diet and 
habits. The full search strategy can be found on PROSPERO with 
registration number CRD42014014717. In addition, all identified 
publications with intake data were screened for relevant data on 
food sources. For data on dietary sources excluding human milk, 
studies were excluded, if the data were collected before 2000. For 
data on human milk, publications from 1990 onwards were in-
cluded because of limited available data published after 2000. 
 Results 
 Evaluation of Recommendations for PUFA Intake in 
European Countries 
 In addition to the EFSA and Food and Agriculture 
 Organisation (FAO)/World Health Organisation (WHO) 
recommendations, we identified 6 individual country 
and 4 multi-country recommendations for PUFA intake. 
In general, recommendations were developed by scien-
tific experts and health authorities after commissioning 
expert systematic evidence-based reviews of mainly hu-
man observational and intervention studies to guide the 
authority’s decision.  Table 1 gives an overview of the rec-
ommendations identified. 
 The criteria used to set specific recommendations 
 ( Table  1 ) are not always clearly described, but include 
provision for adequate growth for infants and children, 
prevention of clinical deficiency and provision for good 
health, encompassing prevention of cardiovascular dis-
eases after the age of 2 years. 
 Mostly, 2 kinds of dietary reference values (DRVs) 
were derived for PUFAs, the AI, for example, set by EFSA 
and many European countries, and the acceptable mac-
ronutrient distribution range, set by FAO/WHO  [19] . 
For LA, the FAO/WHO additionally set an estimated av-
erage requirement. 
 In general, the DRVs for different n-3 and n-6 PUFAs 
for Europe and European countries differ with regard to 
age group, type of fatty acid and unit of expression, which 
made it difficult to compare. In general, DRVs were re-
ported for LA, ALA and EPA + DHA or DHA, while no 
recommendations were reported for DPA, and for ARA 
recommendations were only reported for infants 0–6 
months of age. If guidelines were formulated for pregnant 
and breastfeeding women, they were focused on a spe-
cific increase in the intake of DHA. Recommendations 
for children >2 years of age were not age-specific and 
were often similar to those for adults. For elderly, no rec-
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ommendations were derived, as no specific needs for any 
of the PUFAs were deemed evident. 
 Based on these outcomes, and as explained in the meth-
od section, the EFSA recommendations  [18] have been 
selected to evaluate adequacy of fatty acid intake data in 
the current review. In the absence of EFSA recommenda-
tions for elderly, adult recommendations were used.
 Evaluation of Intake of Total and Specific N-3 and 
N-6 PUFAs 
 Altogether 5,404 titles and abstracts were identified via 
electronic, bibliographic and additional expert searches, 
and 267 of them appeared to be potentially relevant. Fi-
nally, 49 studies fulfilled the inclusion criteria. For preg-
nant women, 10 different publications were included, re-
porting PUFA intake data in 11 different European coun-
tries. For lactating women, only 4 studies from 4 different 
countries were included, all with a limited sample size 
(14–63 women). For infants aged 6–12 months, only 
3 studies from 3 different countries were found, of which 
the study in German infants reported intake data, when 
children were 6 and 9 months old  [20] . For young chil-
dren aged 1–3 years, 6 studies from 6 different countries 
were included. For older children aged 4–9 years, 11 stud-
ies from 10 countries were identified, of which some stud-
ies reported intake in multiple countries. For adolescents 
aged 10–19 years, 8 studies from 11 different countries 
reported data on individual PUFA intake. For elderly 
aged  ≥ 65 years, 11 studies from 9 countries were included 
of which one study from Hungary  [21] reported data in 
elderly aged  ≥ 60 years. Details of intake data can be found 
in online supplementary Tables 1–7.
 In general, intake data were reported for total n-6 
 PUFAs, LA, total n-3 PUFAs, ALA, EPA and DHA, where-
as for DPA and ARA, very little intake data were found. 
 Table 2 gives an overview of available intake data and 
summarises the proportions of countries where current 
intake data were in line with the EFSA recommendations 
for each population group. Detailed information about the 
countries included in each population group can be found 
in the online supplementary Tables 1–7. Across all popula-
tion groups, mean LA intake was below the recommenda-
tion of  ≥ 4 E% in 48% of the countries, with low intake 
more likely in lactating women, adolescents and elderly, 
whereas mean ALA intake was below the recommenda-
tion of  ≥ 0.5 E% in 23% of the countries ( Table 2 ). Across 
all population groups, mean EPA and/or DHA intake was 
lower than the EFSA recommendation in 74% of the coun-
tries, and low intake was of concern in pregnant and lac-
tating women and in infants, children and adolescents. 
 Evaluation of Major Dietary Contributors to 
PUFA Intake 
 Dietary Sources of Individual PUFAs 
 Data on the contribution of different food groups and 
supplements to the intake of various PUFAs were limited 
Table 2.  Overview of European countries meeting n-3 and n-6 PUFA intake recommendations per population group if compared with 







 Evaluation against recommendations (percentage of countries with adequate intake)
total n- 6 PUFAs LA ARAa total n-3 PUFAs ALA EPA + DHA
Recommendations 4.0 E%b 4.0 E% – 0.5 E%b 0.5 E% RI: 250 + 100–200 mg/d DHA
Pregnant women 10 11 6,033 66 (2 out of 3) 75 (3 out of 4) 3 reported 100 (3 out of 3) 100 (4 out of 4) 33 (3 out of 9)
Lactating women 4 4 293 0 (0 out of 1) 0 (0 out of 3) 1 reported 100 (4 out of 4) 100 (2 out of 2) 50 (1 out of 2)
Recommendations 4.0 E%b 4.0 E% – 0.5 E%b 0.5 E% 100.0 mg/d DHAc
Infants 6–12 mo 3 3 606 100 (2 out of 2) 100 (2 out of 2) 1 reported 100 (2 out of 2) 100 (2 out of 2) 0 (0 out of 2)
Children 1–3 y 6 6 1,797 66 (2 out of 3) 75 (3 out of 4) 1 reported 100 (4 out of 4) 75 (3 out of 4) 0 (0 out of 2)c
Recommendations 4.0 E%b 4.0 E% – 0.5 E%b 0.5 E% ≥250.0 mg/d
Children 4–9 y 11 10 10,102 55 (5 out of 9) 66 (2 out of 3) 2 reported 78 (7 out of 9) 100 (3 out of 3) 0 (0 out of 3)
Adolescents 
10–18 y 8 11 4,988 50 (1 out of 2) 44 (4 out of 9) 8 reported 100 (3 out of 3) 70 (7 out of 10) 20 (2 out of 10)
Elderly >65 y 11 9 9,091 66 (2 out of 3) 33 (2 out of 6) 4 reported 66 (2 out of 3) 50 (3 out of 6) 50 (3 out of 6)
Total of all 
population groups 61 (14 out of 23) 52 (16 out of 31) 20 reported 89 (25 out of 28) 77 (24 out of 31) 26 (9 out of 34)
 y, year; mo, months; mg/d, milligrams per day; E%, energy percentage; EFSA, European Food Safety Authority; PUFAs, polyunsaturated fatty acids; LA, linoleic acid; ARA, 
arachidonic acid; n-6, omega-6 PUFA; n-3, omega-3 PUFA; ALA, α-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; RI, reference intake.
a No recommendation, only number of studies with intake data.
b Based on EFSA recommendations for LA and ALA.
c For children >2 y recommendation 250 mg EPA + DHA per day.
 Sioen   et al. Ann Nutr Metab 2017;70:39–50
DOI: 10.1159/000456723
46
to 3 studies, including a Belgian study in children aged 
2.5–6.5 years  [22] , the HELENA study in adolescents 
aged 12.5–17.5 years  [17] and a study in Dutch elderly 
aged  ≥ 70 years  [23] . In Belgian children, fats and oils 
were the major contributors to intakes of LA (23.6%) and 
ALA (33.1%), followed by cereal products with 17.6 and 
13.5%, respectively  [22] . Meat, poultry and eggs were the 
main contributors to ARA intake (72.0%), and fish and 
seafood were the main contributors to EPA (83.5%), 
DPA (57.8%) and DHA (75.7%) intake  [22] . In adoles-
cents in the multiple country HELENA study  [17] , the 
food group “meat, fish, eggs and meat alternatives” was 
the largest contributor to the intake of LA (31.7%), ALA 
(21.5), ARA (54.2%), EPA (92.3%), DPA (94.9%) and 
DHA (85.8%). In Dutch elderly, fats and oils were the 
main contributor to LA (39%) and ALA (36%) intake, 
whereas fish and shellfish (29%) and meat and meat 
products (28%) were the main contributors to EPA and 
DHA intake.
 Individual PUFA Content of Human Milk 
 LA and ALA are the major PUFAs present in human 
milk. According to a review of 14 studies from 9 
 European countries  [24, 25] , the median (range) 
 content  of human milk is 11.0% wt/wt (6.9–16.4) for 
LA and 0.9% wt/wt (0.7–1.3) for ALA. A descriptive me-
ta-analysis including 65 studies of 2,474 women world-
wide indicated a mean ± SD concentration of DHA and 
ARA in human milk of 0.32 ± 0.22 and 0.47 ± 0.13% of 
total fatty acids,  respectively  [26] . European countries 
tended to report higher DHA levels  [27] , with the high-
est DHA concentrations in coastal regions such as 
Greece, Italy and Spain. Detailed information about 
PUFA content of human milk can be found in the on-
line supplementary Table 8  [26] . DHA levels in human 
milk vary considerably among women and are strongly 
influenced by maternal diet, for example, fish and sea-
food intake  [27–30] , whereas ARA concentrations in 
human milk are less sensitive to maternal dietary ARA 
intake  [26, 30] .
 Discussion 
 We provided an overview of the available data on rec-
ommendations, dietary intake and sources of total and 
individual n-3 and n-6 PUFAs in European pregnant 
women, lactating women, infants, young children, older 
children, adolescents and elderly.
 Recommendations 
 Since the review of Aranceta and Pérez-Rodrigo  [15] 
published in 2012, we found that some recommendations 
had not been updated (FAO/WHO, EFSA, The Netherlands, 
Spain), while others had (France, Nordic countries, 
 Belgium). In addition, we identified new recommenda-
tions that were not published at the time of the earlier re-
view (DACH countries – Germany, Austria, Switzerland, 
Poland; France and Spain for infants and children). Similar 
to FAO/WHO and EFSA, no specific dietary recommen-
dations were formulated for elderly in Europe, despite the 
fact that some countries (e.g., France 2001) discussed the 
specific dietary needs of the elderly  [31] . 
 For ARA, recommendations are limited to infants aged 
0–6 months and were based on human milk content. How-
ever, the functional effect of increased ARA intake in this 
age group, and in other age groups, is still much discussed 
 [32, 33] . The role of preformed DHA in visual develop-
ment and brain growth and functioning in foetal life and 
early infancy has been demonstrated and translated into 
specific recommendations for pregnant and lactating 
women and infants. After the age of 2 years, based largely 
on their preventive effect on CVD and beneficial effects for 
neurodevelopment, recommendations have been formu-
lated for EPA + DHA, since these PUFAs are often con-
sumed in combination, for instance in seafood and supple-
ments. In contrast to recommendations in European 
countries and EFSA, some authorities, such as those of 
Australia and New Zealand  [34] have set an AI based on the 
concept of essentiality, that is, on the median intake for 
children and adults in a population without apparent es-
sential fatty acid deficiency, resulting in generally lower 
recommended intakes. While no recommendations for 
DPA were formulated in Europe, the health authority from 
Australia and New Zealand included DPA in its recom-
mendations, that is, the recommended intake for long 
chain n-3 PUFAs including EPA + DPA + DHA.
 Germany and The Netherlands recently reviewed their 
intake recommendations, but did not set any reference 
value for fatty acids, and rather formulated food-based 
dietary guidelines  [35, 36] . Moreover, 2 important au-
thorities, the US Institute of Medicine and the WHO 
 Nutrition Guidance Expert Advisory Group intend to up-
date their PUFA intake recommendations  [37] . In 2014, 
the US and Canadian governments collaboratively indi-
cated that nutrient reference values for n-3 PUFAs need-
ed to be updated with priority, based on public health 
and/or policy importance. The committee is considering 
the incorporation of chronic disease endpoints into the 
setting of dietary reference intake values  [38] .
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 Intake Data 
 In summary, we found that the current information on 
PUFA intake, with especially individual long chain  PUFAs 
in specific age groups being at risk for an inadequate PUFA 
intake across Europe is limited, and identified many gaps 
in the current knowledge. Our findings show that EFSA 
recommendations for intake of LA, ALA and EPA + DHA 
were not met in almost half, a quarter and 3-quarters of the 
countries, respectively. This is in line with findings of ear-
lier studies that have evaluated intakes of these fatty acids 
in children, adolescents and adults worldwide  [12, 13] .
 The lowest number of available studies was found for 
lactating women and infants. However, these population 
groups are of particular interest as PUFA intake is very 
important for rapid brain growth and development dur-
ing infancy. In addition, our findings indicate that there 
is a lack of data on ARA and DPA intakes. The scarcity of 
data on ARA and DPA intakes limits the assessment of 
intake adequacy, especially for at-risk population groups. 
A potential explanation is that information on individual 
PUFAs in the European food composition tables is often 
missing. Therefore, it may be necessary to combine infor-
mation from different food composition tables to make a 
complete estimation of the individual PUFA intake. In 
future, it would be relevant that ARA and DPA are also 
included in food composition analyses. 
 Furthermore, large heterogeneity between studies 
with regard to methodologies and data presentation, 
made it difficult to compare the available intake data 
across countries. First, studies used different methods for 
dietary assessments (e.g., 24 h recall, food frequency 
questionnaires, dietary record). Some of these methods 
assess intake over a short term (1–3 days), which may not 
capture the intake of foods that are not consumed on a 
daily basis (e.g., fish and seafood) and consequently un-
derestimate the intake of EPA and DHA. However, when 
dietary assessments of the study population cover all 
weekdays and seasons, the estimation of mean intakes on 
the population level will be reasonable  [39] . In a limited 
number of identified studies, statistical methods were ap-
plied to correct this between-day variability. However, 
even when diets were evaluated over a longer period, 
foods may have been grouped together (e.g., n-3 PUFA-
rich fish and fish less rich in n-3 PUFAs), which may re-
duce the specificity of intake data. Second, some studies 
took the use of food supplements into consideration  [40–
42] or even selected participants based on very high sea-
food consumption (a survey in French coastal popula-
tions)  [43] , while others specifically excluded fish oil sup-
plement users  [44–46] and some studies just did not 
report whether or not supplements were taken into con-
sideration. Also, in some countries the use of food sup-
plements in general (not specifically, n-3 PUFA supple-
ments) by pregnant and lactating women is quite com-
mon (e.g., in the study of Rodriguez-Bernal, 55.8% of the 
women report the use of multivitamin supplements) 
 [42] , which may explain the large variation in PUFA in-
take. Unfortunately, no data could be found on the aver-
age use of n-3 PUFA supplements by European pregnant 
women, which indicated the need to collect data on sup-
plement use in addition to dietary intake in future stud-
ies. Third, different metrics were used to represent the 
intake data: some studies reported the median, while oth-
ers used the arithmetic or geometric mean, sometimes in 
combination with the standard deviation or with a per-
centile range. This shows a need to harmonise the way 
data on PUFA intake is presented; for example, in case of 
skewed distributions (e.g., EPA and DHA intakes) medi-
ans should be reported. The studies included in our re-
view mainly reported data in means and only a few re-
ported medians. Moreover, comparing the mean PUFA 
intake of a population with PUFA recommendation does 
not allow to determine the percentage of the population 
not meeting the PUFA recommendation. To do so, the 
distribution of the intake in the population has to be 
known. Fourth, different units to express the intake data 
were used: intake of fatty acids can be expressed in (m)g/
day, E% or % of total fat. As it was not always possible to 
convert intake to a common unit based on the available 
information in the publication, comparisons between 
different studies and evaluation of EFSA recommenda-
tions were not possible for some data. 
 This review also showed that information on food and 
food groups contributing to the intake of different  PUFAs, 
and in which amount they contribute, is largely lacking 
and if available, food groups did often report data for indi-
vidual PUFAs and were not comparable between studies. 
 Strengths and Limitations 
 This study has some important strengths. First, the 
overview provided is based on the application of a system-
atic and standardised approach to screen the literature 
and identify the studies to be included. Second, data ex-
traction from the selected studies was conducted in a har-
monised way to obtain useful data for comparison. How-
ever, some limitations also need to be mentioned. First, 
most of the available studies were not based on a random 
sampling procedure or on a national representative sam-
ple. Second, the EFSA recommendations for LA and ALA 
intakes were used to evaluate if intake of total n-6 PUFAs 
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and total n-3 PUFAs was adequate, which may have led to 
an overestimation of countries with sufficient total n-6 
and n-3 PUFA intakes. While the approximation is small 
for n-6 PUFAs (LA contributes on an average to  ∼ 99% of 
total n-6 PUFA intake), it is higher for n-3 PUFAs (ALA 
contributes on an average to  ∼ 80% of n-3 PUFA intake). 
 Recommendations for Future Research 
 Given the limited data available on individual n-3 and 
n-6 PUFA intakes in specific population groups in 
 Europe, our key recommendation is that the EU should 
develop harmonised data collection systems that will 
provide a robust and reliable database on the intake of 
individual PUFAs. This would be needed to establish ev-
idence-based guidelines for public health programs aim-
ing to improve fatty acid intake and for monitoring and 
evaluating the effectiveness of these programs. More-
over, greater national commitment to and consistency in 
the provision of intake data is required to allow reason-
able comparative analyses between different countries. 
Future more detailed intake data should be used to re-
evaluate the current recommendations for the general 
population and specific population groups, including 
those with different pathologies and genetic polymor-
phisms. This would particularly be relevant for ARA and 
DPA for which extremely limited data are available. 
While studies in infants have suggested the role of ARA 
in combination with DHA on physical growth and cog-
nitive development  [47–50] , more recent data indicate 
that ARA and its derivatives may also play key roles in 
cardiovascular, inflammatory and immune functions, 
which have not yet been adequately investigated  [34] . 
Similarly, the potential role of DPA in cardiovascular dis-
ease, immune function and psychiatric and cognitive 
health needs further investigation  [51] .
 Conclusion 
 The available data indicate that mean intake of EPA and 
DHA and to a lesser extent of LA and ALA may be subopti-
mal compared to EFSA recommendations for a significant 
part of specific population groups in Europe. More nation-
ally representative surveys, including subsamples of specif-
ic population groups and data on relevant individual  PUFAs 
are required to clarify the need for specific public health 
measures to optimise PUFA intake in Europe. Also, recom-
mendations for nutrient requirements should be developed 
for the elderly population and recommendations for intake 
of total n-6 and n-3 PUFAs in all population groups.
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